The latest biotech news

News and Trends 18 Nov 2016

14 More Stories: CRISPR enters Humans, Biocartis makes a Splash

Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Biocartis had a big week. The molecular diagnostics company raised €32.7M in an equity […]

November 18, 2016 - 2 minutesmins - By Evelyn Warner

Screenshot 2016 11 18 at 11.23.36 AM e1479464682197

News and Trends 18 Nov 2016

These Spider Silk Sneakers from Adidas Are Biodegradable

Adidas just unveiled a biodegradable sneaker prototype made with a spider silk biomaterial manufactured by the German biotech AMSilk. Is this the beginning of a new era for sustainable biomaterials? AMSilk, located near Munich, is the world’s first biotech supplying synthetic silk biopolymers for textiles, cosmetics and medical devices. The company’s 100% biodegradable and vegan […]

November 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

antibiotic resistance biosensor freiburg

News and Trends 18 Nov 2016

Microfluidics and Biosensors to tackle Antibiotic Resistance

A little biosensor can analyze if there are antibiotics in your blood in 10 minutes. Developed by researchers from the University of Freiburg, the system could be used to develop a personalized course of antibiotics, but also to test food and water. The objective? Slow down the rise of multi-resistant bacteria. The World Antibiotic Awareness […]

November 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

Screenshot 2016 11 17 at 5.37.49 PM e1479400708474

News and Trends 18 Nov 2016

Can Oncolytic Viruses be the key to Treat Resistant Tumors?

This week, we leave Belgium and keep traveling north to Oslo, where snow is starting to pack for the joy of skiers. Meanwhile, Targovax is there working hard to treat cancer with its immunotherapy pipeline. City: Oslo, Norway Founded: 2010 Employees: 20 – 30 Financial data: €12M raised in a private placement in July Mission: Targovax develops immuno-oncology […]

November 18, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 17 Nov 2016

Boehringer’s Biosimilar could take a Chunk out of the Cancer Market

Boehringer Ingelheim is getting ready to launch a biosimilar for Roche’s cancer blockbuster Avastin as soon as the patent expires. Can it overcome the fierce competition in a market expected to grow to 50% of the drug market by 2020? Boehringer Ingelheim just announced results from a Phase I trial showing that its biosimilar candidate […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Nov 2016

Germany steps up the fight against the Most Painful Disease

Grünenthal just acquired Thar Pharmaceuticals to pave the way towards treating complex regional pain syndrome (CRPS), considered one of the most painful conditions. Grünenthal, the company behind the thalidomide scandal in the 60s due to childbirth deformities, is now focusing on complex regional pain syndrome (CRPS), a rare orphan disease that causes prolonged and intense pain. In order […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

card reading fate psychic Miriam Doerr Martin Frommherz fi

News and Trends 17 Nov 2016

What’s in the Cards for a Biosimilar after it Launches

As legal frameworks and regulatory pathways for biosimilars are in evolving all around the world, how will they affect the future of biosimilars? A biosimilar is a biological medicine that is similar to another already authorized for use, and they enter the market after the end of the patent of a biological drug. Biosimilars are […]

November 17, 2016 - 5 minutesmins - By External Contributor

News and Trends 17 Nov 2016

Find Out what’s Hot in the Latin American Biotech scene

You’ve probably heard about BIO-Europe, but what about BIO Latin America? The Latin American counterpart to BIO-Europe, Biolatam, was a success last year: over 250 attending companies from 20 countries participated in 400 one-on-one partnering meetings. Now, Biolatam kicks off in San Juan, Puerto Rico, on November 29th. It will feature over 300 dealmakers representing pharma, biotech and the accompanying […]

November 17, 2016 - 4 minutesmins - By External Contributor

News and Trends 17 Nov 2016

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

UniQure just announced a new R&D plan designed to save up to €27M over the next two years. Will the new strategy be enough to pull it out of its down spiral? UniQure is a Dutch biotech famous for launching Glybera, the first commercial gene therapy worldwide. However, the huge price of the treatment has […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

New Private Placement to Boost the Profitable Therapeutic Antibody Market

MorphoSys has announced a private placement of shares to raise funds for its antibody therapy programs. With this push, the company is solidifying its position as a leader in the therapeutic antibody market, which is expected to reach €117B by 2021. MorphoSys, one of the few European billion euro biotechs, develops therapeutic antibodies for immuno-oncology, inflammatory […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

What if the bacteria in your gut could help fight cancer? Enterome is partnering with Bristol-Myers Squibb to explore this possibility and develop microbiome-related therapeutics and diagnostics for immuno-oncology. Enterome, one of the coolest biotechs in Paris, specializes in the isolation of bacteria and microbial targets linked to immune modulation and inflammation. With an impressive […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

Meet the CEO making the Next Generation of Gene Therapies Possible

How do you solve a problem like lentiviral vector infections? CEVEC has done it. We sat down with the CEO, Frank Ubags, to talk about his company’s success. The last few decades have not been kind to gene therapy companies, but the field seems to be on the edge of a renaissance with adenoviral vectors […]

November 16, 2016 - 6 minutesmins - By External Contributor

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

14 More Stories: CRISPR enters Humans, Biocartis makes a Splash

These Spider Silk Sneakers from Adidas Are Biodegradable

Microfluidics and Biosensors to tackle Antibiotic Resistance

Can Oncolytic Viruses be the key to Treat Resistant Tumors?

Boehringer’s Biosimilar could take a Chunk out of the Cancer Market

Germany steps up the fight against the Most Painful Disease

What’s in the Cards for a Biosimilar after it Launches

Find Out what’s Hot in the Latin American Biotech scene

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

New Private Placement to Boost the Profitable Therapeutic Antibody Market

Microbiomics recruited for Immuno-Oncology in a Huge New Partnership

Meet the CEO making the Next Generation of Gene Therapies Possible

Subscribe to our newsletter to get the latest biotech news!